Lynparza (olaparib) vs Verzenio/Verzenios (abemaciclib)
Lynparza (olaparib) vs Verzenio/Verzenios (abemaciclib)
Lynparza (olaparib) is a PARP inhibitor used primarily for the treatment of certain types of advanced ovarian, breast, pancreatic, and prostate cancers in patients with specific genetic mutations, such as BRCA mutations. Verzenio (abemaciclib), on the other hand, is a CDK4/6 inhibitor indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, often in combination with hormonal therapies. The choice between Lynparza and Verzenio would depend on the cancer type, genetic profile of the tumor, hormone receptor status, and previous treatments, among other individual patient factors, which should be discussed with an oncologist.
Difference between Lynparza and Verzenio/Verzenios
Metric | Lynparza (olaparib) | Verzenio/Verzenios (abemaciclib) |
---|---|---|
Generic name | Olaparib | Abemaciclib |
Indications | Ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations (BRCA1/2 or HRR gene-mutated) | HR-positive, HER2-negative advanced or metastatic breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor |
Brand names | Lynparza | Verzenio (U.S.), Verzenios (EU) |
Administrative route | Oral | Oral |
Side effects | Anemia, nausea, fatigue, vomiting, neutropenia, respiratory infections, leukopenia, diarrhea | Diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, decreased appetite |
Contraindications | Hypersensitivity to olaparib or any of its components | Hypersensitivity to abemaciclib or any of its components, lactation |
Drug class | PARP inhibitor | CDK4/6 inhibitor |
Manufacturer | AstraZeneca and Merck & Co. (MSD outside the US and Canada) | Eli Lilly and Company |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy known as a PARP inhibitor. It has shown efficacy in treating certain types of breast cancer, particularly in patients who have a BRCA mutation. BRCA1 and BRCA2 are genes that produce proteins responsible for repairing damaged DNA. When these genes are mutated, they do not function properly, which can lead to cancer. Olaparib works by exploiting this weakness in cancer cells with BRCA mutations, leading to the death of these cells while sparing normal cells.
Clinical trials have demonstrated that Lynparza significantly improves progression-free survival in patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation. The OlympiAD trial, which compared olaparib to standard chemotherapy, showed that olaparib reduced the risk of disease progression or death by 42%. This indicates a substantial benefit for patients with BRCA-mutated breast cancer, offering a targeted and potentially less toxic alternative to traditional chemotherapy.
Verzenio/Verzenios (Abemaciclib) Efficacy in Breast Cancer
Verzenio, known generically as abemaciclib, is a CDK4/6 inhibitor used in the treatment of certain types of breast cancer. CDK4/6 are proteins that help control cell division. Abemaciclib works by inhibiting these proteins, thereby slowing down the growth of cancer cells. It is specifically indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, often in combination with an aromatase inhibitor or fulvestrant.
The efficacy of Verzenio has been evaluated in several clinical trials. In the MONARCH 2 trial, abemaciclib in combination with fulvestrant demonstrated a significant improvement in progression-free survival compared to fulvestrant alone in women with HR+, HER2- advanced breast cancer who had progressed following endocrine therapy. The MONARCH 3 trial further supported its use in combination with an aromatase inhibitor as initial endocrine-based therapy, showing improved progression-free survival rates. These findings have established Verzenio as an effective option for the management of certain patients with advanced breast cancer.
Regulatory Agency Approvals
Lynparza
Verzenio/Verzenios
Access Lynparza or Verzenio/Verzenios today
If Lynparza or Verzenio/Verzenios are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us